BIBR-1048 Boehringer Ingelheim.
BIBR-1048, a thrombin inhibitor and an orally-active prodrug of BIBR-953ZW, is under development by Boehringer Ingelheim as a potential antithrombotic agent [331881]. By 1999, BIBR-1048 was in phase II clinical trials for thromboembolism and the prevention of stroke due to atrial fibrillation [331881]; by April 2002, proof-of-principle had been demonstrated in phase II trials in deep vein thrombosis [446554]. In July 2001, the company revealed that an IND was expected to be filed for BIBR-953ZW in 2002 [415884].
Mungall
Dennis
D
The Miami Project to Cure Paralysis, Department of Neurological Surgery, University of Miami School of Medicine, Lois Pope Life Center, FL 33101, USA. Thertch@aol.com
D000818:Animals; D001562:Benzimidazoles / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D002545:Brain Ischemia / Q000188:drug therapy*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D000069604:Dabigatran; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D011355:Prodrugs / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D011725:Pyridines / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D013329:Structure-Activity Relationship; D013923:Thromboembolism / Q000188:drug therapy*; D020246:Venous Thrombosis / Q000188:drug therapy*
D001562:Benzimidazoles; D005343:Fibrinolytic Agents; D011355:Prodrugs; D011725:Pyridines; D000069604:Dabigatran